C5AR2

C5a anaphylatoxin chemotactic receptor 2 · Q9P296 · C5AR2 on Sugi Atlas →

58 patent compounds predicted against C5AR2, 36 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Loperamide (SCHEMBL15048)	1.00	1/20
Loperamide (SCHEMBL8409268)	1.00	1/20
Loperamide (SCHEMBL9068543)	1.00	1/20
Loperamide (SCHEMBL21327979)	1.00	1/20
Loperamide (SCHEMBL2346867)	0.98	1/20
Loperamide (SCHEMBL3455728)	0.92	1/20
Loperamide (SCHEMBL2565887)	0.86	1/20
Loperamide (SCHEMBL5082687)	0.86	1/20
Loperamide (SCHEMBL1253778)	0.84	1/20
Loperamide (SCHEMBL675350)	0.80	1/20
Hydrochloric Acid (SCHEMBL7170114)	0.74	1/20
Fluperamide (SCHEMBL7743934)	0.73	1/20
Fluperamide (SCHEMBL29884619)	0.73	1/20
Diphenoxylate (SCHEMBL8157899)	0.69	1/20
Loperamide (SCHEMBL17141900)	0.68	1/20
Loperamide (SCHEMBL7099271)	0.61	1/20
Hydrochloric Acid (SCHEMBL6661629)	0.60	1/20
Hydrochloric Acid (SCHEMBL7738855)	0.59	1/20
Hydrochloric Acid (SCHEMBL7469905)	0.52	1/20
Hydrochloric Acid (SCHEMBL7464664)	0.52	1/20

Clinical trials — most relevant to C5AR2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With aHUS	PHASE4	COMPLETED
A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis	PHASE3	COMPLETED
The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation	PHASE3	COMPLETED
The Effect of Some Drugs Used in Treatment of Vasculitis on the Complement System in Children	PHASE3	UNKNOWN
Ravulizumab and COVID-19	PHASE3	UNKNOWN
Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)	PHASE2	COMPLETED
Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis	PHASE2	COMPLETED
A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis	PHASE2	COMPLETED
Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis.	PHASE2	COMPLETED
Defibrotide TMA Prophylaxis Pilot Trial	PHASE2	COMPLETED
Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum	PHASE2	COMPLETED
Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab	PHASE2	WITHDRAWN
Clinical Assessment of Safety and Tolerability of the New Monoclonal Humanized Antibody CaCP29	PHASE1	COMPLETED
Complement C5a Receptors in Hidradenitis Suppurativa	nan	COMPLETED
Study of the C5a/C5aR1 Axis in IgG4-associated Disease: a Potential Therapeutic Target	nan	NOT_YET_RECRUITING
Complement Activation in the Lysosomal Storage Disorders	nan	WITHDRAWN
C5a Receptor Expression - COVID-19 (C5-COV)	nan	COMPLETED
Genetic Polymorphism Associated With Coronary Heart Disease Susceptibility and Variability of Clopidogrel Response	nan	ACTIVE_NOT_RECRUITING
Anti-C1s, Anti-HMGB1 and Anti-C1q Autoantibodies in Systemic Lupus Erythematosus (DYSALARM-322)	nan	RECRUITING
A Prospective Study of The Complement Depletion in Patients With Severe Abdominal Sepsis	nan	COMPLETED
Kinetics of Nasal Cytokine Responses to Mechanical Stimulation	nan	COMPLETED
Circular RNA and Chemerin in Breast Cancer Patient	nan	UNKNOWN
Genetic Variation and Immune Responses After Injury	nan	UNKNOWN
FGL2/Fibroleukin and Hepatitis C Virus Recurrence Post Liver Transplantation	nan	UNKNOWN
Applying Systems Immunology to the Search for Personalized Biomarkers of Clinical Efficacy	nan	COMPLETED
Effect of Platelet Storage on Complement Activation	nan	UNKNOWN
Assessment of Vitamin D Supplementation and Immune Function	nan	COMPLETED
Transcriptome and Metabolic Analyses of CHAPLE Disease	nan	UNKNOWN
Assessment of CXCL5 Level in SLE Patients and Its Correlation with Disease Activity	nan	NOT_YET_RECRUITING
In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a C5AR2 binder may also engage these)

Protein	Name	Similarity
Q8BW93	—	0.981	Q8BW93 →
Q9Z2J6	—	0.976	Q9Z2J6 →
Q695P6	—	0.975	Q695P6 →
PTGDR2	Prostaglandin D2 receptor 2	0.975	landscape →
O00155	—	0.970	O00155 →
P0C5I1	—	0.969	P0C5I1 →
Q9JL21	—	0.968	Q9JL21 →
Q6XKD3	—	0.968	Q6XKD3 →
RXFP4	Relaxin-3 receptor 2	0.967	landscape →
Q8NGA4	—	0.963	Q8NGA4 →
Q9TUE1	—	0.963	Q9TUE1 →
Q920E0	—	0.963	Q920E0 →
Q76JU9	—	0.962	Q76JU9 →
O70129	—	0.961	O70129 →
Q76JV1	—	0.959	Q76JV1 →
CCR10	C-C chemokine receptor type 10	0.959	landscape →
Q8K3T4	—	0.958	Q8K3T4 →
P2RY11	P2Y purinoceptor 11	0.958	landscape →
P79240	—	0.957	P79240 →
P30993	—	0.956	P30993 →
A0A6I8PUB9	—	0.956	A0A6I8PUB9 →
O88634	—	0.955	O88634 →
P0C7U5	—	0.955	P0C7U5 →
P79175	—	0.955	P79175 →
Q76JU8	—	0.955	Q76JU8 →
C5AR1	C5a anaphylatoxin chemotactic receptor 1	0.954	landscape →
O09027	—	0.954	O09027 →
F2RL3	Proteinase-activated receptor 4	0.954	landscape →
P79188	—	0.954	P79188 →
FFAR1	Free fatty acid receptor 1	0.954	landscape →